Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis.

Date publication

janvier 2020

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Pr PETIT Thierry

Tous les auteurs :
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, De La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31931289

Résumé

The impact of locoregional treatment (LRT) on overall survival (OS) in de novo metastatic breast cancer (dnMBC) is still under debate, with very few data available regarding exclusive radiotherapy (ERT) as a therapeutic modality.

Mots clés

Cohort study, Exclusive radiotherapy, Locoregional treatment, Propensity score, de novo metastatic breast cancer

Référence

Radiother Oncol. 2020 Jan 10;145:109-116